行情

GEMP

GEMP

Gemphire
NASDAQ

实时行情|Nasdaq Last Sale

0.2999
-0.0056
-1.83%
盘后: 0.3060 +0.0061 +2.03% 17:11 12/11 EST
开盘
0.3055
昨收
0.3055
最高
0.3179
最低
0.2701
成交量
11.93万
成交额
--
52周最高
1.485
52周最低
0.2380
市值
446.02万
市盈率(TTM)
-0.3099
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GEMP 新闻

  • Gemphire's stockholder approves NeuroBo merger proposals
  • Seeking Alpha - Article.5天前
  • Gemphire Therapeutics Announces Stockholder Approval Of Proposals Required For Merger With NeuroBo Pharmaceuticals
  • Benzinga.5天前
  • Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals
  • GlobeNewswire.5天前
  • 趣头条Q3净营收14.07亿元 超市场预期
  • 新浪美股.12/03 11:10

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

GEMP 简况

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.
展开

Webull提供Gemphire Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。